


# Treatment 2.0 in Latin America and the Caribbean

Dr. Noreen Jack
Coordinator, PAHO/WHO HIV Caribbean Office
March 19, 2013




## Patients on ART in LAC 2002–2011

2011 ART coverage in Latin America 70%, 67% in the Caribbean, highest in mid-low income settings



WHO. Universal Access progress reports 2010-2012



### Treatment 2.0


I - Optimize Treatment

II – Provide POC and simplified diagnostics tools

**III – Reduce costs** 

IV – Adapt delivery systems


V – Mobilize communities



Achieve and sustain universal access and maximize preventive benefits of treatment


Contributes to the prevention of HIVDR

## Need to Reduce the Number of adult regimens per line of treatment



Conservative level	Moderate level	Expanded level	
1-6 regimens	7-12 regimens	>12 regimens	
Granada, El Salvador, Guyana, Panamá, Brazil, Nicaragua	Peru, Cuba, Argentina, Belice, Paraguay		

### Pillar 1. Optimize drug regimens



### **Objectives:**

- Control HIV infection
- Improved patient adherence
- Increase duration of each regimen

### Preferred Combination of ARV

### 1 st line in Adults and Adolescents:

### **Options 1: 1 FDC per day**

- TDF/3TC/EFV
- TDF/FTC/EFV

#### Evidence:

- Equivalence 3TC and FTC
- > EFV safe in pregnancy
- > TDF licenced for children > 2 a.



One tablet a day a major strategy


Action: Development of ART migration plans

# Pillar 2. POC and other simplified diagnostic and monitoring tools


### **Regional context**

- Limited decentralization of HIV T&C at the primary health care level with complex algorithms and redundant confirmatory tests
- PITC partially implemented mainly in ANC settings
- Insufficient impact of HIV testing strategies in key populations:
   50% of MSM with an HIV test in past year; in sex workers a median of 69%
- Legal policy barriers for HIV testing among adolescents


## % of patients initiating ART with <200 CD4 2000-2011



# Average VL tests per patient on ART 2010



### Pillar 3. Reduce Costs



### Dependence on external funding for ART

	Alta	Media	Baja	Sin dependencia
	>75% - 100% financiación externa de ARV	>20% - 75% financiación externa de ARV	>5% - 20% financiación externa de ARV	>0%-5% financiación externa de ARV
2007-2008	<ul> <li>Antigua y Barbuda</li> <li>Bolivia</li> <li>Dominica</li> <li>Granada</li> <li>Guyana</li> <li>Haití</li> <li>Jamaica</li> <li>Nicaragua</li> <li>República Dominicana</li> <li>St. Kitts y Nevis</li> <li>St. Vicente y las Granadinas</li> <li>St. Lucia</li> <li>Surinam</li> </ul>	<ul> <li>Anguilla</li> <li>Barbados</li> <li>Cuba</li> <li>Guatemala</li> <li>Islas Vírgenes Británicas</li> <li>Monserrat</li> <li>Ecuador</li> <li>El Salvador</li> <li>Honduras</li> <li>Paraguay</li> <li>Belice</li> <li>Perú</li> </ul>		<ul> <li>Argentina</li> <li>Bahamas</li> <li>Brasil</li> <li>Chile</li> <li>Colombia</li> <li>Costa Rica</li> <li>México</li> <li>Panamá</li> <li>Trinidad y Tabago</li> <li>Uruguay</li> <li>Venezuela</li> </ul>
2011-2012	<ul> <li>Antigua y Barbuda</li> <li>Bolivia</li> <li>Dominica</li> <li>Granada</li> <li>Guyana</li> <li>Haití</li> <li>Jamaica</li> <li>Nicaragua</li> <li>Republica Dominicana</li> <li>St. Kitts y Nevis</li> <li>St. Vicente y las Granadinas</li> </ul>	<ul> <li>Anguilla</li> <li>Barbados</li> <li>Cuba</li> <li>Guatemala</li> <li>Monserrat</li> <li>Islas Vírgenes Británicas</li> <li>St. Lucia</li> </ul>	El Salvador     Honduras     Paraguay	<ul> <li>Argentina</li> <li>Bahamas</li> <li>Brasil</li> <li>Chile</li> <li>Colombia</li> <li>Costa Rica</li> <li>México</li> <li>Panamá</li> <li>Trinidad Tabago</li> <li>Uruguay</li> <li>Venezuela</li> <li>Belice</li> <li>Perú</li> <li>Surinam</li> </ul>

Exist 11 countries with high dependency on external funds for the financing of **ART** and high variation on the cost per patient. These countries represent more than 20% with HIV in the Region


### **III. Reduce Costs**

- Most 2<sup>nd</sup> and 3rd line ARVs and many diagnostics are under patent reduction through improved price competition and increasing the use of TRIPS flexibilities where applicable
- Strengthen PSM at all levels
- Pooled procurement as PAHO Strategic Fund
- Regional Platform for the monitoring of ARVs and prevention of stockouts-Honduras, Guatemala, Dominican Republic
- Reducing non-commodity costs
  - up to 75% of ART costs: decentralised chronic care; community delivery systems, task shifting
  - earlier and improved ART will reduce morbidity thus less hospitalization, etc

### Pillar 4. Adapt delivery systems

- Difficult to characterize service delivery models
- Most ART patients
   concentrate in tertiary level
   facilities or dedicated centers
- Limited decentralization of service provision

Percentage alive and on treatment at 12 months of ART initiation, 2011



UNAIDS/WHO. Global HIV/AIDS Response country reported data, 2012.

### **IV. Adapt Delivery Systems**

- Expand opportunities for HIV testing and counselling-links with community and NGOs to reach MARPS
- Decentralize and Integrate ART with PHC, ANC/MCH, SRH and drug dependence services, private sector
- Task-shifting and peer support community systems for adherence & delivery

### V. Mobilize Communities

- Community leadership, participation and activism revitalised
- Strengthen the demand for treatment
- Engage communities in HIV testing and counselling, service delivery and adherence support for care
- Actively promote relevant "positive health and prevention"
- Monitoring to ensure that human rights of PLHIVs are protected and equity in access

### Continuum of care HIV Care and Treatment "CASCADE"

PERSONS WITH HIV


**DIAGNOSIS** 

LINKED TO CARE

RETAINED IN CARE

**ON ART** 

SUPRESSED VIRAL LOAD



Gardner et al. The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection. CID 2011:52

Cohen et al. Vital Signs: HIV Prevention Through Care and Treatment-USA. MMWR 2011;60 Hall et al. HIV in the United States. Stages of care. CDC 2012

### **Treatment 2.0 actitives todate**


- Missions to: ECU, VEN, ELS, DOR, HON; Jamaica, PAR (later in 2013)
- Sub-regional meetings-Southern Cone, Central America; Caribbean in May 2013





Reunión Regional
Acceso y Gestión de los Medicamentos e Insumos Estratégicos para
el VIH/sida en las Américas

Santo Domingo, República Dominicana, del 9 al 11 de noviembre del 2011





MISION TECNICA MULTIDISCIPLINARIA E
INTERPROGRAMATICA PARA LA
OPTIMIZACION DEL TRATAMIENTO
ANTIRRETROVIRAL

**ECUADOR** 

MARZO 2012